"Anti-HIV Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents used to treat AIDS and/or stop the spread of the HIV infection. These do not include drugs used to treat symptoms or opportunistic infections associated with AIDS.
| Descriptor ID |
D019380
|
| MeSH Number(s) |
D27.505.954.122.388.077.088
|
| Concept/Terms |
Anti-HIV Agents- Anti-HIV Agents
- Agents, Anti-HIV
- Anti HIV Agents
- Anti-AIDS Agents
- Agents, Anti-AIDS
- Anti AIDS Agents
- Anti-HIV Drugs
- Anti HIV Drugs
- Drugs, Anti-HIV
- AIDS Drugs
- Drugs, AIDS
- Anti-AIDS Drugs
- Anti AIDS Drugs
- Drugs, Anti-AIDS
|
Below are MeSH descriptors whose meaning is more general than "Anti-HIV Agents".
Below are MeSH descriptors whose meaning is more specific than "Anti-HIV Agents".
This graph shows the total number of publications written about "Anti-HIV Agents" by people in this website by year, and whether "Anti-HIV Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 0 | 1 |
| 1998 | 3 | 2 | 5 |
| 1999 | 3 | 4 | 7 |
| 2000 | 2 | 0 | 2 |
| 2001 | 2 | 0 | 2 |
| 2002 | 2 | 0 | 2 |
| 2003 | 1 | 0 | 1 |
| 2004 | 1 | 0 | 1 |
| 2005 | 2 | 0 | 2 |
| 2007 | 1 | 0 | 1 |
| 2008 | 2 | 0 | 2 |
| 2009 | 3 | 1 | 4 |
| 2011 | 4 | 1 | 5 |
| 2012 | 1 | 1 | 2 |
| 2013 | 4 | 0 | 4 |
| 2014 | 0 | 1 | 1 |
| 2015 | 1 | 1 | 2 |
| 2016 | 5 | 0 | 5 |
| 2017 | 5 | 2 | 7 |
| 2018 | 7 | 2 | 9 |
| 2019 | 5 | 2 | 7 |
| 2020 | 11 | 5 | 16 |
| 2021 | 12 | 6 | 18 |
| 2022 | 6 | 1 | 7 |
| 2023 | 9 | 0 | 9 |
| 2024 | 7 | 7 | 14 |
| 2025 | 11 | 1 | 12 |
| 2026 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Anti-HIV Agents" by people in Profiles.
-
Daily PrEP and event-driven PrEP adherence for men who have sex with men in China. Sex Health. 2026 Feb 05; 23(1).
-
Eligibility and factors associated with long-acting injectable cabotegravir-rilpivirine initiation in an urban academic HIV clinic. J Antimicrob Chemother. 2025 Nov 04; 80(11):3092-3100.
-
Association Between Electronic Patient Portal Enrollment and HIV Care Outcomes Among People Living with HIV at an Urban Academic Medical Center. AIDS Behav. 2026 Jan; 30(1):315-318.
-
Establishing shared definitions of virological failure and discontinuation for long-acting injectable cabotegravir and rilpivirine therapy (the CONSENSUS-LAI Study): an international survey and Delphi process. Lancet HIV. 2025 Sep; 12(9):e649-e659.
-
Preferences for Pre-Exposure Prophylaxis Implementation and Engagement in the HIV Pre-Exposure Prophylaxis Care Continuum Among Patients Receiving Psychiatric Care in an Ending the HIV Epidemic Priority County. J Acquir Immune Defic Syndr. 2025 Aug 01; 99(4):349-358.
-
HIV Viral Rebound on Dolutegravir, Lopinavir, and Efavirenz: National Program Data Analysis From Ukraine. J Acquir Immune Defic Syndr. 2025 Aug 01; 99(4):395-404.
-
The human gut microbiome and its metabolic pathway dynamics before and during HIV antiretroviral therapy. Microbiol Spectr. 2025 Aug 05; 13(8):e0220524.
-
Understanding Opportunities for Prescribing Pre-exposure Prophylaxis at Two Academic Medical Centers in a High Priority Jurisdiction for Ending the HIV Epidemic. AIDS Behav. 2025 Oct; 29(10):3162-3171.
-
Perspectives of healthcare providers in family planning centers on increasing pre-exposure prophylaxis uptake among women who have migrated from sub-Saharan Africa to France. PLoS One. 2025; 20(6):e0325078.
-
Rapid ART, Rapid PrEP, and Status Neutral Implementation in Ryan White-Funded Clinics: Results From a Multisite Survey. J Acquir Immune Defic Syndr. 2025 Apr 15; 98(5S):e136-e145.